You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Targeting neurotoxic alpha-synuclein aggregates for Parkinson's disease therapy.
SBC: Vova Ida, LLC Topic: 999SUMMARYParkinsonandapos s diseasePDis the second most prevalent neurodegenerative disorder after Alzheimerandapos s diseaseADaffecting more thanmillion people in the United StatesBecause age is the major risk factorthe prevalence of both diseases is steadily increasing as our population agesPD belongs to the group of protein misfolding neurodegenerative diseases that are due to the misfolding and ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
DNA-decoded Libraries of Reversible, Covalent Protein Ligands
SBC: DELUGE BIOTECHNOLOGIES INC Topic: 300Project Summary There is increasing interest in the development of covalent ligands of proteinswhich have many advantages over non covalent ligandsThe goal of this proposal is to develop large libraries of DNA encoded libraries of potential covalent ligands and to optimize methods to screen themThis would represent a major advance over current technology to identify covalent ligandswhich almost al ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Improving the pharmacokinetics, potency, and immunogenicity of eCD4-Ig
SBC: EMMUNE INC Topic: NIAIDPROJECT SUMMARY We have developed an antibody like HIVentry inhibitoreCDIgcomposed of the first two domains of CDfused to an antibody Fc domain and a short tyrosine sulfated CCRmimetic peptideeCDIg has properties that make it an exceptionally promising tool in the fight against the HIVpandemicSpecificallyit is broader than any broadly neutralizing antibodybNAbat least as potent at neutralization a ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Audiometric Behavioral Response Simulator
SBC: INTELLIGENT HEARING SYSTEMS CORP Topic: YThe aim of this project is to develop an audiometric testing response simulatorSimulators are quickly becoming a critical component in the training of professionals across all fieldsThe proposed simulator is intended to be used in any environment where behavioral response audiometric testing is conductedthe foundation of most auditory assessmentsThe simulator will have the capability to connect wi ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Product Development of Intensity Modulation for Bolus Electron Conformal Therapy
SBC: Decimal, LLC Topic: 102Project Summary/Abstract Objective: This project aims to elevate electron beam therapy (EBT) technology, which provides effective radiation treatment for superficial cancers (depthandlt;6 cm), to that of other external beam radiotherapies (XRT), e.g. x-rays and protons, by bringing electron intensity modulation into the clinic. Challenge: Approximately 10% of radiotherapy patients (173,000 in U ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
A Phase 2b Clinical Trial to Study the Efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) to Treat Aging Frailty
SBC: Longeveron LLC Topic: NIAAging Frailty is a biologically driven geriatric syndrome of multisystem physiological decline that is distinct from normal aging and disproportionately increases vulnerability to adverse clinical outcomes. Frailty has an overall prevalence of 10% of those 65 years and older, and there is growing awareness in the geriatric community to diagnose and treat this condition, as it is not an inevitable ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Targeting glioblastoma stem-like cells with custom-designed viral vectors
SBC: Lacerta Therapeutics, Inc. Topic: 102Glioblastoma (GBM) is the most lethal form of adult brain cancers with a median survival of andlt;15 months despite aggressive standard chemoradiation. GBM are formed by GBM stem-like cells (GSCs) - a major contributor to tumor recurrence and a natural focus for therapeutic development. There are two main reasons responsible for treatment failure: 1) high intra- and inter-tumor cellular and molecu ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
A Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell (LMSC) Therapy for Treating The Metabolic Syndrome
SBC: Longeveron LLC Topic: NIAThe metabolic syndrome (MetS) is a cluster of factors that increases the risks for cardiovascular disease, type 2 diabetes mellitus, and mortality, and currently affects andgt; 40% of US adults. MetS is associated with endothelial dysfunction, decreased circulating endothelial progenitor cells (EPCs), and a pro-inflammatory state. We have made the exciting discovery that therapy with allogeneic me ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Repurposing of Pyrvinium Pamoate for Familial Adenomatous Polyposis (FAP)
SBC: Stemsynergy Therapeutic Topic: 102ABSTRACT Individuals with the rare, inherited disorder Familial Adenomatous Polyposis (FAP) develop thousands of precancerous polyps at an early age and ultimately develop colorectal cancer (CRC). The current standard of care for FAP is colectomy. However, unavoidable side-effects of colectomy are debilitating. Furthermore, colectomy does not prevent subsequent development of extra-colonic intesti ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Stem Cells for Treating Acute Stroke
SBC: SANERON CCEL THERAPEUTICS, INC. Topic: 999ABSTRACT SUMMARY In previous studies we identified novel non hematopoietic umbilical cord blood stem cellsnhUCBSCsthat could be expanded to high passages and exhibit restorative properties following ischemic brain injury repairWe found that the high passaged cells were equivalentif not even betterthan the low passaged nh UCBSCsThis finding suggests that these cells can serve as a source of highly ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health